- Home
- GLTO vs ZAPP Comparison
GLTO vs ZAPP Comparison
Compare GLTO & ZAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ZAPP
- Stock Information
- Founded
- GLTO 2011
- ZAPP 2017
- Country
- GLTO Denmark
- ZAPP Thailand
- Employees
- GLTO N/A
- ZAPP N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ZAPP Motor Vehicles
- Sector
- GLTO Health Care
- ZAPP Consumer Discretionary
- Exchange
- GLTO Nasdaq
- ZAPP Nasdaq
- Market Cap
- GLTO 7.5M
- ZAPP 6.2M
- IPO Year
- GLTO 2020
- ZAPP N/A
- Fundamental
- Price
- GLTO $4.70
- ZAPP $1.30
- Analyst Decision
- GLTO Buy
- ZAPP
- Analyst Count
- GLTO 1
- ZAPP 0
- Target Price
- GLTO $10.00
- ZAPP N/A
- AVG Volume (30 Days)
- GLTO 20.6K
- ZAPP 159.5K
- Earning Date
- GLTO 11-01-2024
- ZAPP 12-31-2024
- Dividend Yield
- GLTO N/A
- ZAPP N/A
- EPS Growth
- GLTO N/A
- ZAPP N/A
- EPS
- GLTO N/A
- ZAPP N/A
- Revenue
- GLTO N/A
- ZAPP N/A
- Revenue This Year
- GLTO N/A
- ZAPP N/A
- Revenue Next Year
- GLTO N/A
- ZAPP $53,347.33
- P/E Ratio
- GLTO N/A
- ZAPP N/A
- Revenue Growth
- GLTO N/A
- ZAPP N/A
- 52 Week Low
- GLTO $4.40
- ZAPP $0.70
- 52 Week High
- GLTO $23.50
- ZAPP $19.10
- Technical
- Relative Strength Index (RSI)
- GLTO 26.70
- ZAPP 28.94
- Support Level
- GLTO $4.40
- ZAPP $1.32
- Resistance Level
- GLTO $5.42
- ZAPP $1.87
- Average True Range (ATR)
- GLTO 0.37
- ZAPP 0.17
- MACD
- GLTO -0.01
- ZAPP -0.00
- Stochastic Oscillator
- GLTO 16.81
- ZAPP 6.15
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ZAPP Zapp Electric Vehicles Group Limited
Zapp Electric Vehicles Group Ltd designs manufactures, and sells high-performance electric vehicles, including maintenance and repair of electric vehicles and related parts and accessories.